Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Imaxio Signs an Option for a License Agreement with Merial

Published: Tuesday, December 18, 2012
Last Updated: Tuesday, December 18, 2012
Bookmark and Share
This option agreement confirms the potential of Imaxio’s antigen re-engineering technology to improve human and animal health vaccines.

Imaxio has announced the signing of an option for a license agreement with Merial, the animal health division of Sanofi.

The aim of this agreement is to develop an animal health vaccine based on Imaxio’s immune-enhancing IMX313 technology.

Merial will conduct an internal review of the IMX313 technology for a period of 12 to 18 months and depending on results, will sign a license agreement.

Details of the vaccine candidate and the financial terms of the agreement have not been disclosed.

The aim of IMX313, Imaxio’s proprietary technology for antigen re-engineering, is to significantly enhance the immune response and therefore, the efficacy of vaccines with which it is used.

In response to the challenge of certain inefficacious vaccine candidates, IMX313 is a high-potential solution, which would not only enable the dose to be reduced but also the number of revaccinations needed.

"This agreement with a world leader in the animal health sector such as Merial further confirms the significance of our IMX313 technology in developing more efficacious vaccines," said Alexandre Le Vert, managing director of Imaxio.

Vert continued, "We are committed to pursuing partnerships to license our immune-enhancing IMX313 technology for new indications. This will enable us to offer even more innovative solutions for key players in the animal health sector and on a larger scale, for vaccinations in general."

“Merial is a clear leader in the development and commercial registration of new vaccine technologies in animal health. We are very pleased to assess the progress of Imaxio’s IMX313 technology and this fits very well into the current strategic needs of Merial,” said Jean-Christophe Audonnet, senior director, research strategy and key alliances, Bio R&D Merial.

Audonnet continued, “This collaboration is an excellent example of the increase in opportunities created in the Lyonbiopole regional cluster.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Imaxio Signs an Option for a License Agreement with DKFZ
Imaxio’s pro-immunogenic technology will be tested to enhance the efficacy of a candidate vaccine for the human papillomavirus.
Friday, October 17, 2014
Imaxio Boosts Genomics Capacity with New Automated Equipment
Investment means larger scale, faster high throughput sequencing for Imaxio customers.
Friday, June 29, 2012
Imaxio Closes EUR 2.9 Million Funding Round
Funding will enable the clinical development of its IMX313 carrier protein platform for vaccines, and update the marketing authorization application it filed in France.
Wednesday, April 18, 2012
Scientific News
How it Works: Advanced Data Analysis Using Visualization
Visualisation of data can be used to help molecular biologists tackle the vast datasets their experiments create.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Influential Cancer Researcher Receives Agilent Thought Leader Award
Biologist Scott Lowe receives award in recognition for his contributions to cancer biology.
Molecular Origins of Dust Mite Allergy Discovered
Scientists have identified molecules of house dust mites that are targeted by the immune system of children, developing allergic rhinitis and asthma.
Gene-Editing Cures Genetic Blood Disorder in Mice
New technology may offer minimally invasive treatment for genetic disorders of the blood.
Epigenetics and Neural Cell Death
Researchers demonstrate how deregulation of an epigenetic mechanism active in early neurogenesis phases triggers neural cell death.
ALS Study Reveals Role of RNA-Binding Proteins
The findings are a significant step forward in validating RNA-based therapy as a treatment for ALS.
New Compound Shows Promise in Treating Multiple Human Cancers
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of all cancers.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Lab-on-a-Chip to Help Detect Cancer
In this podcast, we speak to Gustavo Stolovitsky to learn about his career and the work he is doing at IBM Research.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos